Search for: [Abstract = "rterial thrombosis. Angina, acute thrombosis, diabetes, haemorrhagic diathesis, autoimmune diseases, hypo\- or hyperthyroidism, acute inflammation, medication usage \(beside antihypertensive drugs\) and severe comorbidities were the exclusion criteria for both groups. Study participants received atorvastatin \(Sortis, Pfizer\) 40 mg\/day for 3 days. Fasting blood was collected before intake of the first dose and after 3 days of atorvastatin administration. Lipid profiles, high\-sensitivity C\-reactive protein \(CRP\), other serum routine parameters, fibrinogen concentrations, D\-dimers, prothrombin fragment 1.2 \(F1.2\), tissue plasminogen activator \(t\-PA\), plasminogen activator inhibitor\-1 \(PAI\-1\), lipoprotein\(a\) \[Lp\(a\)\] and total homocysteine \(tHcy\) were determined. \; Plasma fibrin clot properties were expressed as permeation coefficient \(Ks\), turbidity measurements of fibrin polymerization \[lag phase, maximum absorbance \(Δ Abs\)\], plasma clot lysis assays in presence of recombinant tissue\-type plasminogen activator \(rtPA\) with \(t50%\) or without \(CLT\) exogenous thrombin and D\-dimer levels \[maximum concentration \(D\-D max\) and rate of increase \(D\-D rate\)\] in a fibrin clot perfusion model. The location of venous thrombosis in VTE patients was analyzed. Screening for thrombophilia and residual venous thrombosis \(RVT\) detection were also performed. Two groups did not differ with respect to demo"]

Number of results: 1